[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fqwjDsyA2rTbak_mcN8AEQ1GmV5pSfkm7Ye8duqPdDJQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"AHS Cancer Control Alberta",[4],186,false,38,9,27027,31,118,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Prostate Cancer",17,{"name":18,"count":19},"Breast Cancer",13,{"name":21,"count":22},"Head and Neck Cancer",7,{"name":24,"count":25},"Cancer",6,{"name":27,"count":28},"Breast Neoplasms",5,{"name":30,"count":28},"Colorectal Cancer",{"name":32,"count":28},"Healthy",{"name":34,"count":28},"Lung Neoplasms",[36,41,46,51,56,61,66,71,75,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02238808","A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers","2018-07-30","Estradiol",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03391973","Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)","2023-06-16","Pembrolizumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04952480","Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer","2025-11-01","Chemotherapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04354649","Immune-Mediated Pathophysiology And Clinical Triage Program","2026-07","Hydroxychloroquine",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05663775","Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab\u002FNivolumab (Ipi\u002FNivo)","2026-08","Mesalamine",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05451043","Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","2026-10-01","Durvalumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04765098","Tamoxifen Versus Etoposide After First Recurrence in GBM Patients","2026-12","Tamoxifen",{"nctId":72,"briefTitle":73,"date":69,"intervention":74},"NCT02632305","A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","nab-paclitaxel in combination with gemcitabine + cisplatin",{"nctId":76,"briefTitle":77,"date":69,"intervention":78},"NCT04268199","A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment","Bortezomib",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05421416","Loratadine for the Prevention of G-CSF-related Bone Pain","2026-12-01","Loratadine",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,122,168,197,220,245,268,286,311,336,366,384,402,420,438,460,486,512,532,553,574,600,623,647,669,694,750,774,807,825,843,861,879,897,933,958,976,994,1021,1046,1070,1095,1120,1145,1163,1189,1207,1225,1250,1275,1300,1326,1350,1378,1396,1414,1441,1459,1485,1508,1532,1566,1584,1610,1631,1656,1681,1706,1730,1760,1783,1808,1834,1852,1879,1897,1923,1947,1969,1994,2019,2043,2068,2086],{"intervention":93,"totalTrials":94,"cells":95},"Ferric derisomaltose",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":118,"NA":120},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":94,"soonestReadout":110},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"NCT05407987","Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)","RECRUITING",[88],"2026-12-30","2025-04-08",82,[114,115,116],"Gynecologic Cancer","Anemia","Iron-deficiency",[93],{"trials":119,"activeCount":98},[],{"trials":121,"activeCount":98},[],{"intervention":123,"totalTrials":124,"cells":125},"Olaparib",2,{"EARLY_PHASE1":126,"PHASE1":145,"PHASE2":147,"PHASE3":162,"PHASE4":164,"NA":166},{"trials":127,"activeCount":94,"soonestReadout":132},[128],{"nctId":129,"briefTitle":130,"status":108,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":140},"NCT05432518","Pilot Trial for Treatment of Recurrent Glioblastoma",[85],"2027-07-01","2027-12-01","2023-06-27",10,[137,138,139],"Glioblastoma","Recurrent Disease","Recurrent Glioblastoma",[141,142,143,144,123],"Afatinib","Dasatinib","Palbociclib","Everolimus",{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":94,"soonestReadout":154},[149],{"nctId":150,"briefTitle":151,"status":152,"phases":153,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":160},"NCT05128734","Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","NOT_YET_RECRUITING",[87],"2028-04-01","2028-07-01","2026-04-01",40,[159],"Breast Cancer Triple Negative",[161,123],"Temozolomide",{"trials":163,"activeCount":98},[],{"trials":165,"activeCount":98},[],{"trials":167,"activeCount":98},[],{"intervention":161,"totalTrials":124,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":180,"PHASE4":193,"NA":195},{"trials":171,"activeCount":98},[],{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":94,"soonestReadout":154},[176],{"nctId":150,"briefTitle":151,"status":152,"phases":177,"primaryCompletion":154,"completion":155,"start":156,"enrollment":157,"conditions":178,"interventions":179},[87],[159],[161,123],{"trials":181,"activeCount":98},[182],{"nctId":183,"briefTitle":184,"status":185,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":98,"conditions":190,"interventions":191},"NCT01830101","A Phase III Study of Re-Irradiation in Recurrent Glioblastoma","WITHDRAWN",[88],"2015-05","2017-11","2014-02",[139],[192,161],"TMZ plus concurrent re-irradiation",{"trials":194,"activeCount":98},[],{"trials":196,"activeCount":98},[],{"intervention":40,"totalTrials":94,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":200,"activeCount":98},[],{"trials":202,"activeCount":98},[],{"trials":204,"activeCount":94,"soonestReadout":39},[205],{"nctId":37,"briefTitle":38,"status":206,"phases":207,"primaryCompletion":39,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"ACTIVE_NOT_RECRUITING",[87],"2028-06","2015-08",19,[212],"Estrogen Receptor Positive Breast Cancer",[40],{"trials":215,"activeCount":98},[],{"trials":217,"activeCount":98},[],{"trials":219,"activeCount":98},[],{"intervention":221,"totalTrials":94,"cells":222},"Scheduling of the time of pembrolizumab infusions",{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":239,"PHASE4":241,"NA":243},{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":98},[],{"trials":228,"activeCount":94,"soonestReadout":233},[229],{"nctId":230,"briefTitle":231,"status":152,"phases":232,"primaryCompletion":233,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT06882174","This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer",[87],"2028-07","2026-05",58,[237],"Metastatic Non Small Cell Lung Cancer",[221],{"trials":240,"activeCount":98},[],{"trials":242,"activeCount":98},[],{"trials":244,"activeCount":98},[],{"intervention":70,"totalTrials":94,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":94,"soonestReadout":69},[253],{"nctId":67,"briefTitle":68,"status":108,"phases":254,"primaryCompletion":69,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},[87],"2027-07","2022-01-28",60,[259],"Glioblastoma Multiforme",[70,261],"Etoposide",{"trials":263,"activeCount":98},[],{"trials":265,"activeCount":98},[],{"trials":267,"activeCount":98},[],{"intervention":261,"totalTrials":94,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":271,"activeCount":98},[],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":94,"soonestReadout":69},[276],{"nctId":67,"briefTitle":68,"status":108,"phases":277,"primaryCompletion":69,"completion":255,"start":256,"enrollment":257,"conditions":278,"interventions":279},[87],[259],[70,261],{"trials":281,"activeCount":98},[],{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":98},[],{"intervention":60,"totalTrials":94,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":305,"PHASE4":307,"NA":309},{"trials":289,"activeCount":98},[],{"trials":291,"activeCount":98},[],{"trials":293,"activeCount":94,"soonestReadout":59},[294],{"nctId":57,"briefTitle":58,"status":108,"phases":295,"primaryCompletion":59,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":304},[87],"2027-08","2024-08-20",20,[300,301,302,303],"Immune-related Adverse Event","Diarrhea","Advanced Melanoma","Advanced Rectal Carcinoma",[60],{"trials":306,"activeCount":98},[],{"trials":308,"activeCount":98},[],{"trials":310,"activeCount":98},[],{"intervention":312,"totalTrials":94,"cells":313},"Levothyroxine Oral Tablet [Synthroid]",{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":315,"activeCount":98},[],{"trials":317,"activeCount":98},[],{"trials":319,"activeCount":94,"soonestReadout":324},[320],{"nctId":321,"briefTitle":322,"status":152,"phases":323,"primaryCompletion":324,"completion":325,"start":69,"enrollment":326,"conditions":327,"interventions":329},"NCT06790589","COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer",[87],"2027-12","2031-01",70,[328],"Advanced Differentiated Thyroid Gland Carcinoma",[312],{"trials":331,"activeCount":98},[],{"trials":333,"activeCount":98},[],{"trials":335,"activeCount":98},[],{"intervention":65,"totalTrials":94,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":342,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":339,"activeCount":98},[],{"trials":341,"activeCount":98},[],{"trials":343,"activeCount":94,"soonestReadout":64},[344],{"nctId":62,"briefTitle":63,"status":108,"phases":345,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":354},[87],"2029-10-01","2023-07-05",62,[350,351,352,353],"Pancreatic Cancer","Hepatocellular Cancer","Biliary Tract Cancer","Cholangiocarcinoma",[65,355,356,357,358,359],"Gemcitabine","Nab paclitaxel","Tremelimumab","Propranolol","Cisplatin",{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"intervention":356,"totalTrials":94,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":369,"activeCount":98},[],{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":94,"soonestReadout":64},[374],{"nctId":62,"briefTitle":63,"status":108,"phases":375,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":376,"interventions":377},[87],[350,351,352,353],[65,355,356,357,358,359],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"intervention":357,"totalTrials":94,"cells":385},{"EARLY_PHASE1":386,"PHASE1":388,"PHASE2":390,"PHASE3":396,"PHASE4":398,"NA":400},{"trials":387,"activeCount":98},[],{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":94,"soonestReadout":64},[392],{"nctId":62,"briefTitle":63,"status":108,"phases":393,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":394,"interventions":395},[87],[350,351,352,353],[65,355,356,357,358,359],{"trials":397,"activeCount":98},[],{"trials":399,"activeCount":98},[],{"trials":401,"activeCount":98},[],{"intervention":358,"totalTrials":94,"cells":403},{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"trials":409,"activeCount":94,"soonestReadout":64},[410],{"nctId":62,"briefTitle":63,"status":108,"phases":411,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":412,"interventions":413},[87],[350,351,352,353],[65,355,356,357,358,359],{"trials":415,"activeCount":98},[],{"trials":417,"activeCount":98},[],{"trials":419,"activeCount":98},[],{"intervention":359,"totalTrials":94,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":94,"soonestReadout":64},[428],{"nctId":62,"briefTitle":63,"status":108,"phases":429,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":430,"interventions":431},[87],[350,351,352,353],[65,355,356,357,358,359],{"trials":433,"activeCount":98},[],{"trials":435,"activeCount":98},[],{"trials":437,"activeCount":98},[],{"intervention":45,"totalTrials":94,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":94,"soonestReadout":44},[446],{"nctId":42,"briefTitle":43,"status":206,"phases":447,"primaryCompletion":44,"completion":448,"start":449,"enrollment":450,"conditions":451,"interventions":453},[87],"2025-12-30","2018-08-24",26,[452],"Carcinoma of Unknown Primary",[45],{"trials":455,"activeCount":98},[],{"trials":457,"activeCount":98},[],{"trials":459,"activeCount":98},[],{"intervention":461,"totalTrials":94,"cells":462},"[68]Ga-HA-DOTATATE",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":94,"soonestReadout":473},[469],{"nctId":470,"briefTitle":471,"status":108,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT03145857","A Study to Evaluate a New Way to Identify\u002FDiagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use",[86,87],"2040-08","2046-08","2020-03-05",1534,[478],"Neuroendocrine Tumors",[461],{"trials":481,"activeCount":98},[],{"trials":483,"activeCount":98},[],{"trials":485,"activeCount":98},[],{"intervention":487,"totalTrials":94,"cells":488},"Arm 2- Budesonide (Pulmicort® Turbuhaler®) + Usual care",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":94,"soonestReadout":499},[495],{"nctId":496,"briefTitle":497,"status":108,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":502,"conditions":503,"interventions":505},"NCT06860542","Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis",[87],"2029-12-01","2030-12-01","2026-02-10",94,[504,300],"Pneumonitis",[487],{"trials":507,"activeCount":98},[],{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"intervention":50,"totalTrials":94,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":94,"soonestReadout":49},[520],{"nctId":47,"briefTitle":48,"status":108,"phases":521,"primaryCompletion":49,"completion":49,"start":522,"enrollment":11,"conditions":523,"interventions":525},[87],"2022-06-13",[524],"Small Cell Lung Cancer",[50],{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":98},[],{"intervention":83,"totalTrials":94,"cells":533},{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":547,"PHASE4":549,"NA":551},{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":98},[],{"trials":539,"activeCount":94,"soonestReadout":82},[540],{"nctId":80,"briefTitle":81,"status":108,"phases":541,"primaryCompletion":82,"completion":82,"start":542,"enrollment":543,"conditions":544,"interventions":546},[87],"2024-11-28",78,[545],"Stem Cell Transplant Complications",[83],{"trials":548,"activeCount":98},[],{"trials":550,"activeCount":98},[],{"trials":552,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":556,"activeCount":98},[],{"trials":558,"activeCount":98},[],{"trials":560,"activeCount":94,"soonestReadout":69},[561],{"nctId":72,"briefTitle":73,"status":206,"phases":562,"primaryCompletion":69,"completion":69,"start":563,"enrollment":564,"conditions":565,"interventions":567},[87],"2016-07-13",45,[566],"Unresectable Biliary Tract Cancer",[74],{"trials":569,"activeCount":98},[],{"trials":571,"activeCount":98},[],{"trials":573,"activeCount":98},[],{"intervention":575,"totalTrials":94,"cells":576},"Carboplatin and Taxol",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":578,"activeCount":98},[],{"trials":580,"activeCount":98},[],{"trials":582,"activeCount":94,"soonestReadout":587},[583],{"nctId":584,"briefTitle":585,"status":108,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":593},"NCT02297217","Chemoradiotherapy for Advanced Esophageal Cancer",[87],"2027-04-30","2028-04-30","2019-11-21",50,[592],"Esophageal Cancer",[575],{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":601},{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":603,"activeCount":98},[],{"trials":605,"activeCount":98},[],{"trials":607,"activeCount":94,"soonestReadout":54},[608],{"nctId":52,"briefTitle":53,"status":108,"phases":609,"primaryCompletion":54,"completion":610,"start":611,"enrollment":612,"conditions":613,"interventions":616},[87],"2029-07","2021-09-16",46,[614,615],"Arthritis","Arthralgia",[55],{"trials":618,"activeCount":98},[],{"trials":620,"activeCount":98},[],{"trials":622,"activeCount":98},[],{"intervention":624,"totalTrials":94,"cells":625},"Chemo-Radiotherapy with concurrent temozolomide.",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":94,"soonestReadout":636},[632],{"nctId":633,"briefTitle":634,"status":108,"phases":635,"primaryCompletion":636,"completion":636,"start":637,"enrollment":638,"conditions":639,"interventions":640},"NCT04765514","Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients",[87],"2032-06","2022-07-27",107,[259],[624],{"trials":642,"activeCount":98},[],{"trials":644,"activeCount":98},[],{"trials":646,"activeCount":98},[],{"intervention":78,"totalTrials":94,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":663,"PHASE4":665,"NA":667},{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":94,"soonestReadout":69},[655],{"nctId":76,"briefTitle":77,"status":108,"phases":656,"primaryCompletion":69,"completion":69,"start":657,"enrollment":658,"conditions":659,"interventions":662},[87],"2020-05-29",100,[660,661],"Myeloma","Myeloma Multiple",[78],{"trials":664,"activeCount":98},[],{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"intervention":670,"totalTrials":94,"cells":671},"[177]Lu-DOTA-TATE",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":688,"PHASE4":690,"NA":692},{"trials":673,"activeCount":98},[],{"trials":675,"activeCount":98},[],{"trials":677,"activeCount":94,"soonestReadout":682},[678],{"nctId":679,"briefTitle":680,"status":108,"phases":681,"primaryCompletion":682,"completion":682,"start":683,"enrollment":684,"conditions":685,"interventions":687},"NCT01876771","A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours",[87],"2042-12","2014-04-29",500,[686],"Carcinoma, Neuroendocrine",[670],{"trials":689,"activeCount":98},[],{"trials":691,"activeCount":98},[],{"trials":693,"activeCount":98},[],{"intervention":355,"totalTrials":695,"cells":696},4,{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":720,"PHASE4":734,"NA":736},{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"trials":702,"activeCount":94,"soonestReadout":64},[703,716],{"nctId":704,"briefTitle":705,"status":706,"phases":707,"primaryCompletion":708,"completion":708,"start":709,"enrollment":658,"conditions":710,"interventions":714},"NCT02295722","GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed\u002F Refractory Lymphoma","TERMINATED",[86,87],"2023-02","2015-04",[711,712,713],"Hodgkin's Lymphoma - Relapsed\u002FRefractory","Non-Hodgkin's Lymphoma - Aggressive","Follicular Lymphoma",[355,715],"Melphalan",{"nctId":62,"briefTitle":63,"status":108,"phases":717,"primaryCompletion":64,"completion":346,"start":347,"enrollment":348,"conditions":718,"interventions":719},[87],[350,351,352,353],[65,355,356,357,358,359],{"trials":721,"activeCount":98},[722],{"nctId":723,"briefTitle":724,"status":725,"phases":726,"primaryCompletion":709,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},"NCT01586611","A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer","UNKNOWN",[88],"2015-06","2012-06",175,[731],"Metastatic Pancreas Cancer",[733,355],"5FU, leucovorin, oxaliplatin",{"trials":735,"activeCount":98},[],{"trials":737,"activeCount":98},[738],{"nctId":739,"briefTitle":740,"status":725,"phases":741,"primaryCompletion":742,"completion":743,"start":744,"enrollment":298,"conditions":745,"interventions":747},"NCT01411072","Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer",[90],"2015-09","2015-12","2011-09",[746],"Pancreas Cancer",[748,749],"gemcitabine","5-fluorouracil",{"intervention":142,"totalTrials":124,"cells":751},{"EARLY_PHASE1":752,"PHASE1":758,"PHASE2":760,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":753,"activeCount":94,"soonestReadout":132},[754],{"nctId":129,"briefTitle":130,"status":108,"phases":755,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":756,"interventions":757},[85],[137,138,139],[141,142,143,144,123],{"trials":759,"activeCount":98},[],{"trials":761,"activeCount":98},[762],{"nctId":763,"briefTitle":764,"status":185,"phases":765,"enrollment":98,"conditions":766,"interventions":767},"NCT01410708","TORI 104 Pre-Surgical Dasatinib",[87],[18],[142],{"trials":769,"activeCount":98},[],{"trials":771,"activeCount":98},[],{"trials":773,"activeCount":98},[],{"intervention":775,"totalTrials":124,"cells":776},"GCAR1",{"EARLY_PHASE1":777,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":778,"activeCount":94,"soonestReadout":793},[779,789],{"nctId":780,"briefTitle":781,"status":782,"phases":783,"primaryCompletion":784,"completion":784,"start":785,"enrollment":94,"conditions":786,"interventions":788},"NCT06827886","GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma","COMPLETED",[85],"2024-09-09","2023-09-06",[787],"Alveolar Soft Part Sarcoma",[775],{"nctId":790,"briefTitle":791,"status":206,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":94,"conditions":795,"interventions":796},"NCT06789081","GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)",[85],"2028-03-01","2024-02-01",[787],[775],{"trials":798,"activeCount":98},[],{"trials":800,"activeCount":98},[],{"trials":802,"activeCount":98},[],{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"intervention":141,"totalTrials":94,"cells":808},{"EARLY_PHASE1":809,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":810,"activeCount":94,"soonestReadout":132},[811],{"nctId":129,"briefTitle":130,"status":108,"phases":812,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":813,"interventions":814},[85],[137,138,139],[141,142,143,144,123],{"trials":816,"activeCount":98},[],{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"intervention":143,"totalTrials":94,"cells":826},{"EARLY_PHASE1":827,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":828,"activeCount":94,"soonestReadout":132},[829],{"nctId":129,"briefTitle":130,"status":108,"phases":830,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":831,"interventions":832},[85],[137,138,139],[141,142,143,144,123],{"trials":834,"activeCount":98},[],{"trials":836,"activeCount":98},[],{"trials":838,"activeCount":98},[],{"trials":840,"activeCount":98},[],{"trials":842,"activeCount":98},[],{"intervention":144,"totalTrials":94,"cells":844},{"EARLY_PHASE1":845,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":846,"activeCount":94,"soonestReadout":132},[847],{"nctId":129,"briefTitle":130,"status":108,"phases":848,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":849,"interventions":850},[85],[137,138,139],[141,142,143,144,123],{"trials":852,"activeCount":98},[],{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[],{"intervention":192,"totalTrials":94,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":875,"NA":877},{"trials":864,"activeCount":98},[],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[],{"trials":870,"activeCount":98},[871],{"nctId":183,"briefTitle":184,"status":185,"phases":872,"primaryCompletion":187,"completion":188,"start":189,"enrollment":98,"conditions":873,"interventions":874},[88],[139],[192,161],{"trials":876,"activeCount":98},[],{"trials":878,"activeCount":98},[],{"intervention":733,"totalTrials":94,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":893,"NA":895},{"trials":882,"activeCount":98},[],{"trials":884,"activeCount":98},[],{"trials":886,"activeCount":98},[],{"trials":888,"activeCount":98},[889],{"nctId":723,"briefTitle":724,"status":725,"phases":890,"primaryCompletion":709,"completion":727,"start":728,"enrollment":729,"conditions":891,"interventions":892},[88],[731],[733,355],{"trials":894,"activeCount":98},[],{"trials":896,"activeCount":98},[],{"intervention":898,"totalTrials":124,"cells":899},"Epirubicin",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":904,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[906,918],{"nctId":907,"briefTitle":908,"status":706,"phases":909,"completion":910,"start":911,"enrollment":590,"conditions":912,"interventions":915},"NCT00130936","Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric\u002FGastroesophageal Junction Cancer With Pharmacogenetic Correlates",[86,87],"2007-11","2005-10",[913,592,914],"Gastric Cancer","Tumors",[898,916,917],"Carboplatin","Capecitabine",{"nctId":919,"briefTitle":920,"status":725,"phases":921,"primaryCompletion":727,"completion":922,"start":923,"enrollment":924,"conditions":925,"interventions":926},"NCT01740271","A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients",[87],"2025-06","2012-12",48,[27],[898],{"trials":928,"activeCount":98},[],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"intervention":934,"totalTrials":94,"cells":935},"Lenalidomide",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[942],{"nctId":943,"briefTitle":944,"status":782,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":157,"conditions":949,"interventions":951},"NCT00322985","A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma",[87],"2014-05","2014-07","2006-06",[950],"T-cell Lymphoma",[934],{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"intervention":916,"totalTrials":94,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":961,"activeCount":98},[],{"trials":963,"activeCount":98},[],{"trials":965,"activeCount":98},[966],{"nctId":907,"briefTitle":908,"status":706,"phases":967,"completion":910,"start":911,"enrollment":590,"conditions":968,"interventions":969},[86,87],[913,592,914],[898,916,917],{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"intervention":917,"totalTrials":94,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":988,"PHASE4":990,"NA":992},{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[984],{"nctId":907,"briefTitle":908,"status":706,"phases":985,"completion":910,"start":911,"enrollment":590,"conditions":986,"interventions":987},[86,87],[913,592,914],[898,916,917],{"trials":989,"activeCount":98},[],{"trials":991,"activeCount":98},[],{"trials":993,"activeCount":98},[],{"intervention":995,"totalTrials":94,"cells":996},"SU011248",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":998,"activeCount":98},[],{"trials":1000,"activeCount":98},[],{"trials":1002,"activeCount":98},[1003],{"nctId":1004,"briefTitle":1005,"status":782,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1014},"NCT00578526","SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial",[87],"2014-07-16","2008-04",64,[1011,1012,1013],"Urothelial Cancer","Bladder Cancer","Adult",[995],{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":98},[],{"intervention":1022,"totalTrials":94,"cells":1023},"Combination Product: Nivolumab with Pemetrexed",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1040,"PHASE4":1042,"NA":1044},{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"trials":1029,"activeCount":98},[1030],{"nctId":1031,"briefTitle":1032,"status":782,"phases":1033,"primaryCompletion":1034,"completion":1035,"start":1036,"enrollment":25,"conditions":1037,"interventions":1039},"NCT04107103","Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma",[87],"2023-04-14","2023-04-28","2020-03-19",[1038],"SCCHN",[1022],{"trials":1041,"activeCount":98},[],{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"intervention":1047,"totalTrials":94,"cells":1048},"Glucocorticoid therapy",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":98},[],{"trials":1054,"activeCount":98},[1055],{"nctId":1056,"briefTitle":1057,"status":706,"phases":1058,"primaryCompletion":1059,"completion":1059,"start":1060,"enrollment":124,"conditions":1061,"interventions":1063},"NCT04461418","Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases",[87],"2023-09-23","2021-03-30",[1062],"Brain Metastases, Adult",[1047],{"trials":1065,"activeCount":98},[],{"trials":1067,"activeCount":98},[],{"trials":1069,"activeCount":98},[],{"intervention":1071,"totalTrials":94,"cells":1072},"Cemiplimab",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[1079],{"nctId":1080,"briefTitle":1081,"status":185,"phases":1082,"primaryCompletion":1083,"completion":1084,"start":1085,"enrollment":98,"conditions":1086,"interventions":1088},"NCT05538988","BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma",[86,87],"2025-02","2026-03","2024-12",[1087],"Mycosis Fungoides",[1071],{"trials":1090,"activeCount":98},[],{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":98},[],{"intervention":1096,"totalTrials":94,"cells":1097},"Glutamine",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":98},[1104],{"nctId":1105,"briefTitle":1106,"status":782,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1113},"NCT00255229","Study of Glutamine as Prophylaxis for Irinotecan Induced Diarrhea",[87],"2010-01","2002-12",130,[1112],"Metastatic Colorectal Cancer",[1096],{"trials":1115,"activeCount":98},[],{"trials":1117,"activeCount":98},[],{"trials":1119,"activeCount":98},[],{"intervention":1121,"totalTrials":94,"cells":1122},"C-PERT",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":98},[],{"trials":1128,"activeCount":98},[1129],{"nctId":1130,"briefTitle":1131,"status":185,"phases":1132,"primaryCompletion":1133,"enrollment":98,"conditions":1134,"interventions":1137},"NCT01747512","An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)",[87],"2013-05",[1135,1136],"Thyroid Neoplasms","Head and Neck Neoplasms",[1121,1138],"G-PERT",{"trials":1140,"activeCount":98},[],{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[],{"intervention":1138,"totalTrials":94,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1148,"activeCount":98},[],{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":98},[1153],{"nctId":1130,"briefTitle":1131,"status":185,"phases":1154,"primaryCompletion":1133,"enrollment":98,"conditions":1155,"interventions":1156},[87],[1135,1136],[1121,1138],{"trials":1158,"activeCount":98},[],{"trials":1160,"activeCount":98},[],{"trials":1162,"activeCount":98},[],{"intervention":1164,"totalTrials":94,"cells":1165},"18F-FAZA PET scan",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1183,"PHASE4":1185,"NA":1187},{"trials":1167,"activeCount":98},[],{"trials":1169,"activeCount":98},[],{"trials":1171,"activeCount":98},[1172],{"nctId":1173,"briefTitle":1174,"status":706,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1181},"NCT00771381","A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer",[87],"2019-02-04","2008-11-28",23,[1180],"Breast Neoplasm",[1164,1182],"FluGlucoScan Injection (18F-FDB) PET scan",{"trials":1184,"activeCount":98},[],{"trials":1186,"activeCount":98},[],{"trials":1188,"activeCount":98},[],{"intervention":1182,"totalTrials":94,"cells":1190},{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[1197],{"nctId":1173,"briefTitle":1174,"status":706,"phases":1198,"primaryCompletion":1176,"completion":1176,"start":1177,"enrollment":1178,"conditions":1199,"interventions":1200},[87],[1180],[1164,1182],{"trials":1202,"activeCount":98},[],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"intervention":715,"totalTrials":94,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[1215],{"nctId":704,"briefTitle":705,"status":706,"phases":1216,"primaryCompletion":708,"completion":708,"start":709,"enrollment":658,"conditions":1217,"interventions":1218},[86,87],[711,712,713],[355,715],{"trials":1220,"activeCount":98},[],{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"intervention":1226,"totalTrials":94,"cells":1227},"Metformin",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1229,"activeCount":98},[],{"trials":1231,"activeCount":98},[],{"trials":1233,"activeCount":98},[1234],{"nctId":1235,"briefTitle":1236,"status":706,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT01996696","Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate",[87],"2020-11","2014-09",83,[1242],"Prostatic Neoplasm",[1226],{"trials":1245,"activeCount":98},[],{"trials":1247,"activeCount":98},[],{"trials":1249,"activeCount":98},[],{"intervention":1251,"totalTrials":94,"cells":1252},"[18]F-PSMA-1007",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1254,"activeCount":98},[],{"trials":1256,"activeCount":98},[],{"trials":1258,"activeCount":98},[1259],{"nctId":1260,"briefTitle":1261,"status":706,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1268},"NCT05712174","A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer",[87],"2025-05-05","2023-09-14",176,[1267,15],"Oncology",[1251],{"trials":1270,"activeCount":98},[],{"trials":1272,"activeCount":98},[],{"trials":1274,"activeCount":98},[],{"intervention":1276,"totalTrials":94,"cells":1277},"18F-FAZA PET Imaging",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[1284],{"nctId":1285,"briefTitle":1286,"status":706,"phases":1287,"primaryCompletion":1176,"completion":1176,"start":1288,"enrollment":1289,"conditions":1290,"interventions":1293},"NCT00323076","[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours",[86,87],"2006-09-12",92,[1291,1292],"Renal Cell Carcinoma","Neuroendocrine Tumours",[1276],{"trials":1295,"activeCount":98},[],{"trials":1297,"activeCount":98},[],{"trials":1299,"activeCount":98},[],{"intervention":1301,"totalTrials":94,"cells":1302},"Irinotecan-Capecitabine-Oxaliplatin",{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1320,"PHASE4":1322,"NA":1324},{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[1309],{"nctId":1310,"briefTitle":1311,"status":782,"phases":1312,"primaryCompletion":1313,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1319},"NCT01129310","First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.",[87],"2018-05-18","2010-07",47,[1317,1318],"Gastrointestinal Neoplasm","Gastric Adenocarcinoma",[1301],{"trials":1321,"activeCount":98},[],{"trials":1323,"activeCount":98},[],{"trials":1325,"activeCount":98},[],{"intervention":1327,"totalTrials":94,"cells":1328},"Sublingual Methadone",{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":98},[1335],{"nctId":1336,"briefTitle":1337,"status":706,"phases":1338,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":28,"conditions":1341,"interventions":1343},"NCT00351715","Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients",[87],"2008-09","2008-07",[24,1342],"Pain",[1327],{"trials":1345,"activeCount":98},[],{"trials":1347,"activeCount":98},[],{"trials":1349,"activeCount":98},[],{"intervention":1351,"totalTrials":94,"cells":1352},"Irinotecan",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1354,"activeCount":98},[],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[1359],{"nctId":1360,"briefTitle":1361,"status":782,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":22,"conditions":1366,"interventions":1369},"NCT04808791","iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",[87],"2023-07-07","2023-07-21","2021-10-27",[1367,1368],"Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma",[1351,1370,1371],"Oxaliplatin","TAS 102",{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":98},[],{"intervention":1370,"totalTrials":94,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"trials":1385,"activeCount":98},[1386],{"nctId":1360,"briefTitle":1361,"status":782,"phases":1387,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":22,"conditions":1388,"interventions":1389},[87],[1367,1368],[1351,1370,1371],{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"trials":1395,"activeCount":98},[],{"intervention":1371,"totalTrials":94,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":98},[],{"trials":1401,"activeCount":98},[],{"trials":1403,"activeCount":98},[1404],{"nctId":1360,"briefTitle":1361,"status":782,"phases":1405,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":22,"conditions":1406,"interventions":1407},[87],[1367,1368],[1351,1370,1371],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"intervention":1415,"totalTrials":94,"cells":1416},"Treatment Arm - high dose ATG",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[],{"trials":1422,"activeCount":98},[1423],{"nctId":1424,"briefTitle":1425,"status":706,"phases":1426,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1430,"interventions":1433},"NCT03456817","HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis",[87],"2025-05-31","2020-07-01",68,[1431,1432],"Graft-versus-host-disease","Relapse",[1415,1434],"Control Arm - standard of care",{"trials":1436,"activeCount":98},[],{"trials":1438,"activeCount":98},[],{"trials":1440,"activeCount":98},[],{"intervention":1434,"totalTrials":94,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1444,"activeCount":98},[],{"trials":1446,"activeCount":98},[],{"trials":1448,"activeCount":98},[1449],{"nctId":1424,"briefTitle":1425,"status":706,"phases":1450,"primaryCompletion":1427,"completion":1427,"start":1428,"enrollment":1429,"conditions":1451,"interventions":1452},[87],[1431,1432],[1415,1434],{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":98},[],{"trials":1458,"activeCount":98},[],{"intervention":1460,"totalTrials":94,"cells":1461},"Niacin CRT",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[1468],{"nctId":1469,"briefTitle":1470,"status":1471,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1478},"NCT04677049","Study of Niacin in Glioblastoma","SUSPENDED",[86,87],"2026-12-31","2021-03-18",59,[1477],"Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",[1460],{"trials":1480,"activeCount":98},[],{"trials":1482,"activeCount":98},[],{"trials":1484,"activeCount":98},[],{"intervention":1486,"totalTrials":94,"cells":1487},"BIBF1120",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":98},[1494],{"nctId":1495,"briefTitle":1496,"status":185,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":947,"enrollment":98,"conditions":1499,"interventions":1501},"NCT02152059","A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy",[87],"2016-07",[524,1500],"Platinum-sensitive",[1486],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"intervention":1509,"totalTrials":94,"cells":1510},"Rosuvastatin",{"EARLY_PHASE1":1511,"PHASE1":1513,"PHASE2":1515,"PHASE3":1526,"PHASE4":1528,"NA":1530},{"trials":1512,"activeCount":98},[],{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[1517],{"nctId":1518,"briefTitle":1519,"status":782,"phases":1520,"primaryCompletion":1521,"completion":1521,"start":1522,"enrollment":564,"conditions":1523,"interventions":1525},"NCT02569645","Rosuvastatin in the Treatment of Rectal Cancer",[87],"2021-09-24","2015-11",[1524],"Rectal Cancer",[1509],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":98},[],{"trials":1531,"activeCount":98},[],{"intervention":1533,"totalTrials":94,"cells":1534},"Valproic Acid",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1536,"activeCount":98},[],{"trials":1538,"activeCount":98},[],{"trials":1540,"activeCount":98},[1541],{"nctId":1542,"briefTitle":1543,"status":782,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1548,"conditions":1549,"interventions":1558},"NCT03357757","Avelumab With Valproic Acid in Virus-associated Cancer",[87],"2022-03-30","2025-03-31","2018-02-07",39,[1550,1551,1552,1553,1554,1555,1556,1557],"Cancer That is Associated With a Chronic Viral Infection","p16 Positive SCCHN","Squamous Cell Carcinoma of the Cervix","p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva","p16 Positive Squamous Cell Carcinoma of the Penis","p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal","EBER Positive NPC","EBER Positive Hodgkins and Non-hodgkins Lymphona",[1533,1559],"Avelumab",{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"intervention":1559,"totalTrials":94,"cells":1567},{"EARLY_PHASE1":1568,"PHASE1":1570,"PHASE2":1572,"PHASE3":1578,"PHASE4":1580,"NA":1582},{"trials":1569,"activeCount":98},[],{"trials":1571,"activeCount":98},[],{"trials":1573,"activeCount":98},[1574],{"nctId":1542,"briefTitle":1543,"status":782,"phases":1575,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":1548,"conditions":1576,"interventions":1577},[87],[1550,1551,1552,1553,1554,1555,1556,1557],[1533,1559],{"trials":1579,"activeCount":98},[],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"intervention":1585,"totalTrials":94,"cells":1586},"18F-FLT",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1588,"activeCount":98},[],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[1593],{"nctId":1594,"briefTitle":1595,"status":706,"phases":1596,"primaryCompletion":1597,"completion":1597,"start":1598,"enrollment":502,"conditions":1599,"interventions":1603},"NCT01065805","A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma",[86,87],"2019-02-25","2009-03-20",[1600,24,1601,1602],"Brain Cancer","Solid Tumor","Lymphoma",[1585],{"trials":1605,"activeCount":98},[],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"intervention":1611,"totalTrials":94,"cells":1612},"90Y-ibritumomab tiuxetan",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"trials":1618,"activeCount":98},[1619],{"nctId":1620,"briefTitle":1621,"status":185,"phases":1622,"enrollment":98,"conditions":1623,"interventions":1624},"NCT00414089","Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL",[87],[1602],[1611],{"trials":1626,"activeCount":98},[],{"trials":1628,"activeCount":98},[],{"trials":1630,"activeCount":98},[],{"intervention":1632,"totalTrials":94,"cells":1633},"CP-675,206",{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1638,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1635,"activeCount":98},[],{"trials":1637,"activeCount":98},[],{"trials":1639,"activeCount":98},[1640],{"nctId":1641,"briefTitle":1642,"status":782,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":1645,"enrollment":1646,"conditions":1647,"interventions":1649},"NCT01034787","Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma",[87],"2017-08-08","2009-08-17",11,[1648],"Uveal Melanoma",[1632],{"trials":1651,"activeCount":98},[],{"trials":1653,"activeCount":98},[],{"trials":1655,"activeCount":98},[],{"intervention":1657,"totalTrials":94,"cells":1658},"Avelumab and Radical radiotherapy",{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[1665],{"nctId":1666,"briefTitle":1667,"status":706,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":1671,"conditions":1672,"interventions":1674},"NCT03737721","The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy",[87],"2024-07-15","2019-04-12",8,[1673],"Squamous Cell Carcinoma of the Skin",[1657],{"trials":1676,"activeCount":98},[],{"trials":1678,"activeCount":98},[],{"trials":1680,"activeCount":98},[],{"intervention":1682,"totalTrials":94,"cells":1683},"Methotrexate",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[1690],{"nctId":1691,"briefTitle":1692,"status":706,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":1697,"conditions":1698,"interventions":1699},"NCT06001125","Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)",[87],"2025-06-17","2025-10-07","2024-08-12",27,[614,615],[1682],{"trials":1701,"activeCount":98},[],{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"intervention":1707,"totalTrials":94,"cells":1708},"Trifluridine\u002FTipiracil",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1724,"PHASE4":1726,"NA":1728},{"trials":1710,"activeCount":98},[],{"trials":1712,"activeCount":98},[],{"trials":1714,"activeCount":98},[1715],{"nctId":1716,"briefTitle":1717,"status":185,"phases":1718,"primaryCompletion":1719,"completion":1719,"start":1720,"enrollment":98,"conditions":1721,"interventions":1723},"NCT04149444","A Study of Trifluridine\u002FTipiracil in Triple Negative Metastatic Breast Cancer",[87],"2020-06-09","2020-02",[1722],"Metastatic Triple Negative Breast Cancer",[1707],{"trials":1725,"activeCount":98},[],{"trials":1727,"activeCount":98},[],{"trials":1729,"activeCount":98},[],{"intervention":1731,"totalTrials":124,"cells":1732},"Dichloroacetate",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1752,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[1737,1743],{"nctId":1738,"briefTitle":1739,"status":185,"phases":1740,"primaryCompletion":1108,"start":1340,"enrollment":98,"conditions":1741,"interventions":1742},"NCT00703859","Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma",[86],[137],[1731],{"nctId":1744,"briefTitle":1745,"status":782,"phases":1746,"primaryCompletion":1747,"completion":1747,"start":1748,"enrollment":1178,"conditions":1749,"interventions":1751},"NCT00566410","A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and\u002For Metastatic Solid Tumours",[86],"2013-03","2007-12",[1750],"Neoplasms",[1731],{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[],{"intervention":1761,"totalTrials":94,"cells":1762},"Methadone",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[1767],{"nctId":1768,"briefTitle":1769,"status":782,"phases":1770,"primaryCompletion":948,"completion":1771,"start":1772,"enrollment":135,"conditions":1773,"interventions":1774},"NCT00125294","Sublingual Methadone for the Management of Cancer Breakthrough Pain",[86],"2007-01","2003-09",[24,1342],[1761],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[],{"intervention":1784,"totalTrials":94,"cells":1785},"Imatinib Oral",{"EARLY_PHASE1":1786,"PHASE1":1788,"PHASE2":1800,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1787,"activeCount":98},[],{"trials":1789,"activeCount":98},[1790],{"nctId":1791,"briefTitle":1792,"status":706,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":1796,"conditions":1797,"interventions":1799},"NCT03469011","A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.",[86],"2024-07-31","2018-09-18",14,[1798],"Papillary Thyroid Cancer",[1784],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[],{"intervention":1809,"totalTrials":94,"cells":1810},"CPERT",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1826,"PHASE3":1828,"PHASE4":1830,"NA":1832},{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[1815],{"nctId":1816,"briefTitle":1817,"status":782,"phases":1818,"primaryCompletion":1819,"completion":1820,"start":1821,"enrollment":1822,"conditions":1823,"interventions":1824},"NCT01437254","To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer",[86],"2012-04","2015-01","2011-10",30,[1135],[1809,1825],"GPERT",{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[],{"trials":1833,"activeCount":98},[],{"intervention":1825,"totalTrials":94,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[1840],{"nctId":1816,"briefTitle":1817,"status":782,"phases":1841,"primaryCompletion":1819,"completion":1820,"start":1821,"enrollment":1822,"conditions":1842,"interventions":1843},[86],[1135],[1809,1825],{"trials":1845,"activeCount":98},[],{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"intervention":1853,"totalTrials":94,"cells":1854},"Theophylline",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1871,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1856,"activeCount":98},[],{"trials":1858,"activeCount":98},[1859],{"nctId":1860,"briefTitle":1861,"status":706,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1239,"enrollment":1865,"conditions":1866,"interventions":1869},"NCT02080078","A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline",[86],"2019-03-30","2019-04-30",15,[1867,1868],"Non-small Cell Lung Cancer","Advanced Solid Malignancies",[1853,1870],"Erlotinib",{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[],{"trials":1876,"activeCount":98},[],{"trials":1878,"activeCount":98},[],{"intervention":1870,"totalTrials":94,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1882,"activeCount":98},[],{"trials":1884,"activeCount":98},[1885],{"nctId":1860,"briefTitle":1861,"status":706,"phases":1886,"primaryCompletion":1863,"completion":1864,"start":1239,"enrollment":1865,"conditions":1887,"interventions":1888},[86],[1867,1868],[1853,1870],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[],{"intervention":1898,"totalTrials":94,"cells":1899},"Regorafenib",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1915,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1901,"activeCount":98},[],{"trials":1903,"activeCount":98},[1904],{"nctId":1905,"briefTitle":1906,"status":185,"phases":1907,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":98,"conditions":1911,"interventions":1914},"NCT02439723","Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients",[86],"2017-06","2017-12","2016-03",[1912,1913],"Metastatic Solid Malignancies","Locally Advanced Solid Malignancies",[1898],{"trials":1916,"activeCount":98},[],{"trials":1918,"activeCount":98},[],{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"intervention":1924,"totalTrials":94,"cells":1925},"ABT-888\u002FBortezomib",{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1939,"PHASE3":1941,"PHASE4":1943,"NA":1945},{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[1930],{"nctId":1931,"briefTitle":1932,"status":782,"phases":1933,"primaryCompletion":1934,"completion":1935,"start":1821,"enrollment":210,"conditions":1936,"interventions":1938},"NCT01495351","Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma",[86],"2015-02","2015-02-10",[1937],"Multiple Myeloma",[1924],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"trials":1946,"activeCount":98},[],{"intervention":1948,"totalTrials":94,"cells":1949},"[18]F-FLT PET scan",{"EARLY_PHASE1":1950,"PHASE1":1959,"PHASE2":1961,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1951,"activeCount":98},[1952],{"nctId":1953,"briefTitle":1954,"status":706,"phases":1955,"primaryCompletion":1956,"completion":1956,"start":910,"enrollment":1646,"conditions":1957,"interventions":1958},"NCT00414570","An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs",[85],"2019-02-06",[350],[1948],{"trials":1960,"activeCount":98},[],{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[],{"trials":1968,"activeCount":98},[],{"intervention":1970,"totalTrials":94,"cells":1971},"5FU\u002FLV",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1973,"activeCount":98},[],{"trials":1975,"activeCount":98},[],{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":98},[],{"trials":1981,"activeCount":98},[],{"trials":1983,"activeCount":98},[1984],{"nctId":1985,"briefTitle":1986,"status":725,"phases":1987,"primaryCompletion":1988,"completion":1988,"start":1989,"enrollment":1990,"conditions":1991,"interventions":1993},"NCT00131599","Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer",[],"2017-07","2002-08",104,[1992],"Colon Cancer",[1970],{"intervention":1995,"totalTrials":94,"cells":1996},"R-CHOP",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2005,"NA":2007},{"trials":1998,"activeCount":98},[],{"trials":2000,"activeCount":98},[],{"trials":2002,"activeCount":98},[],{"trials":2004,"activeCount":98},[],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[2009],{"nctId":2010,"briefTitle":2011,"status":782,"phases":2012,"primaryCompletion":189,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2018},"NCT00530179","FDG-PET-Stratified R-DICEP and R-Beam\u002FASCT For Diffuse Large B-Cell Lymphoma",[90],"2015-05-19","2007-07",69,[2017],"Diffuse Large B Cell Lymphoma",[1995],{"intervention":2020,"totalTrials":94,"cells":2021},"Oral administration of stable isotope",{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2028,"PHASE4":2030,"NA":2032},{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":98},[2034],{"nctId":2035,"briefTitle":2036,"status":706,"phases":2037,"primaryCompletion":1821,"completion":1821,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2042},"NCT00962234","Metabolism of Lipids in Advanced Cancer",[],"2009-10",12,[34,2041],"Cachexia",[2020],{"intervention":2044,"totalTrials":94,"cells":2045},"FEC 100",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2056},{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[],{"trials":2055,"activeCount":98},[],{"trials":2057,"activeCount":98},[2058],{"nctId":2059,"briefTitle":2060,"status":706,"phases":2061,"primaryCompletion":2062,"completion":2063,"start":2064,"enrollment":2065,"conditions":2066,"interventions":2067},"NCT00131612","An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment",[],"2005-12","2013-01","2002-01",120,[18],[2044],{"intervention":749,"totalTrials":94,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[2082],{"nctId":739,"briefTitle":740,"status":725,"phases":2083,"primaryCompletion":742,"completion":743,"start":744,"enrollment":298,"conditions":2084,"interventions":2085},[90],[746],[748,749],{"intervention":2087,"totalTrials":94,"cells":2088},"Lu-177 DOTA-TATE",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[],{"trials":2100,"activeCount":98},[2101],{"nctId":2102,"briefTitle":2103,"status":725,"phases":2104,"primaryCompletion":2105,"completion":2105,"start":2106,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT01763554","Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014",[],"2025-12","2012-08",115,[2109],"Neuroendocrine Tumors, NET",[2087]]